Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report

Twenty patients with signs of tardive dyskinesia secondary to antipsychotic medication participated in a double blind, controlled, parallel group study comparing codergocrine mesylate 4.5 mg once daily with a placebo. After 6 weeks medication a reduction in dyskinetic scores occurred in both groups, but at the end of a further 6-week period the patients on active treatment maintained their improvement while those on placebo did not. This may be due to a slow onset of action and a hangover of activity associated with the drug.